69 results
8-K
EX-99.1
COCP
Cocrystal Pharma Inc
1 May 24
Enrollment Completed in Phase 2a Study with Cocrystal Pharma’s Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal Influenza
8:00am
Exhibit 99.1
Enrollment Completed in Phase 2a Study with Cocrystal Pharma’s Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal Influenza … treatment designed to effectively block an essential step in the viral replication and transcription of pandemic and seasonal influenza A, and was discovered
8-K
EX-99.1
COCP
Cocrystal Pharma Inc
6 Dec 23
Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza A
8:00am
Exhibit 99.1
Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal … -patient-in for the Phase 2a human challenge clinical trial with CC-42344, an investigational new oral antiviral inhibitor for the treatment of pandemic
8-K
EX-99.1
COCP
Cocrystal Pharma Inc
4 Jan 24
Cocrystal Pharma Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investigational Candidates
4:01pm
of pandemic and seasonal influenza A. CDI-988 and CC-42344 were specifically designed and developed using Cocrystal’s unique structure-based drug discovery … and co-CEO. “We see great promise with both of these drug candidates as potential effective oral treatments for highly contagious, pandemic viruses
8-K
EX-99.1
COCP
Cocrystal Pharma Inc
11 May 22
Cocrystal Pharma Reports First Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs and Milestones
8:30am
Reported favorable preliminary data from the two initial cohorts in its Phase 1 study with CC-42344 for the treatment of pandemic and seasonal … CEO of Cocrystal. “With our oral PB2 inhibitor, CC-42344 for the treatment of pandemic and seasonal influenza A, we announced favorable preliminary
8-K
EX-99.1
COCP
Cocrystal Pharma Inc
19 Mar 24
Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A
8:30am
as a potential oral treatment for pandemic and seasonal influenza A. A Pre-IND review provides the opportunity to obtain FDA guidance and clarification … -42344 Influenza A PB2 Inhibitor
CC-42344 is a novel, broad-spectrum, investigational antiviral candidate for the treatment of pandemic and seasonal
8-K
EX-99.1
emec6h ytnry1y
16 Aug 23
Cocrystal Pharma Reports Second Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
4:05pm
8-K
EX-99.1
lz4kn
31 Oct 23
Cocrystal Pharma Receives UK MHRA Authorization to Initiate Its Phase 2a Influenza Human Challenge Trial with Oral PB2 Inhibitor CC-42344
8:00am
8-K
EX-99.1
kucj2i
26 Oct 22
Enrollment Completed in Phase 1 Influenza A Study with Cocrystal Pharma’s Oral Antiviral Candidate CC-42344
8:00am
8-K
EX-99.1
sux5 ff45h1
15 Nov 21
Cocrystal Pharma Reports Third Quarter Financial Results and Provides an Update on Development
8:00am
8-K
EX-99.1
vngncrd0xq
23 Mar 22
Cocrystal Pharma Reports 2021 Financial Results and Provides Updates on Development Programs and Milestones
4:05pm
8-K
EX-99.1
qbanzn mudjnx66o82f
13 Nov 23
Cocrystal Pharma Reports Third Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
8:15am
8-K
EX-99.2
gjcg5pb
29 Nov 23
Regulation FD Disclosure
8:00am
8-K
EX-99.1
8kpaguaf
15 May 23
Cocrystal Pharma Reports First Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
8:00am
8-K
EX-99.1
4ehi2k6 w7lo
15 Aug 22
Cocrystal Pharma Reports Second Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs
8:00am
8-K
kq6a 334t4z43vam88bf
4 Jan 24
Cocrystal Pharma Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investigational Candidates
4:01pm
8-K
EX-99.1
d1y25wzlcl
28 Mar 24
Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
8:00am